Board of Directors.

Dr. Stanley Marks, MD is the ​Chairman of UPMC's Hillman Cancer Center, the Chief of the Division of Hematology-Oncology at UPMC Shadyside, and a Clinical Professor of Medicine at the University of Pittsburgh. Dr. Marks is a world-recognized leader in cancer research having served as President of The Leukemia & Lymphoma Society and on the board of directors of the American Cancer Society, among others. He is also a leading clinician and noted advocate for patients. He is consistently listed among the “Best Cancer Doctors in America” and his patients have founded the Dr. Stanley Marks Research Endowed fund at the Hillman Cancer Center which has raised $7 million for cancer research to date. Dr. Marks has served as chairman of the board at multiple oncology companies including Via Oncology, CTS International and CytoAgents.

Dr. Sam Rothstein, PhD is the CEO and cofounder of Duo Oncology. He has 20 experience researching and developing nanoparticle products like the ones licensed by Duo Onocology. Since founding and bootstrapping his first company in 2010, a particle CDMO, Dr. Rothstein has continuously worked in life science startups as a CSO or CEO. During this time, he led $5 million of contracts and Small Business Innovation Research projects developing particle drug products. As a CEO, he has also raised over $4M in private investment since 2020. Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer immunotherapy and drug delivery as the CEO of Qrono Inc in 2017. Dr. Rothstein holds chemical engineering degrees from Bucknell University and the University of Pittsburgh.

Dr. Lusong Luo, PhD is currently SVP & Head of External Innovation at BeiGene. Prior to taking this role, Dr. Luo is SVP & Head of Discovery Biology at BeiGene and is also one of the company’s founding scientists. He concurrently serves as the acting CEO and president of MapKure, LLC, and sits on the boards of MapKure, BITT (Boston Immune Technologies & Therapeutics) and two other early-stage biotech firms. Before his tenure at BeiGene, Dr. Luo held significant roles at BioDuro and GSK Oncology. As a key member of numerous oncology drug discovery-development teams, Dr. Luo has contributed to the discovery and development of 15 clinical assets over the years, among them six have obtained regulatory approval. Dr. Luo has published more than 60 research papers, reviews, and book chapters. He trained with Prof. Christopher T. Walsh at Harvard Medical School and obtained his Ph.D. in Biochemistry from University of New Mexico.

Dr. Song Li, MD, PhD is the David and Betty Brenneman Professor & Director of the Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy. Dr. Li’s major research area is drug and gene delivery. He also investigates nuclear receptors and gene regulation. Dr. Li has broad knowledge in medicine, biology, and drug and gene delivery. He is the author or co-author of over 220 peer-reviewed articles and book chapters. Dr. Li serves on the editorial boards of several journals and the review panels of NIH, DOD and other funding agencies.

Dr. Jing-Zhou Hou, MD, PhD, is a clinical hematological oncologist specializing in hematological malignancies, cell therapy, and bone marrow transplant in the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center. Dr. Hou is a clinical investigator focusing on lymphoma and acute myeloid leukemia (AML). He has been conducting many cutting-edge clinical trials such as bispecific T-cell engagers and immunological and targeted therapies. Many of these trials have led to FDA approvals of the investigational agents such as venetoclax, ibrutinib, and polatuzumab.

Joe Gatto is the Managing Director of seedfolio, a venture capital firm based in San Diego, CA. Previously, Joe was founder and CEO of StarMine where he successfully fundraised, built a successful team, and sold the company to Thomson Reuters (now Refinitiv) for $100m. Since the sale of the company, Joe turned to seed investing and has made +45 investments in early stage companies through 2 funds. The analytical approach he takes to quantifying risk-adjusted returns for potential investments stems from his studies into the mathematics (and psychology) of decision sciences while earning his master’s degree at Stanford.

Dr. Victoria Manax, M.D. is an accomplished medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry with a focus on global drug/device development, medical affairs, and patient advocacy. Dr. Manax has made indelible contributions to the field with her expertise in shaping clinical trial landscapes, particularly in adaptive platform designs with biomarker integration. Renowned for these innovative clinical trial designs, Dr. Manax has played a pivotal role in the development, approval, and launch of billion-dollar products, including the standard of care for pancreatic cancer. Dr. Manax has effectively overseen numerous multimillion-dollar global clinical trial programs, earning her recognition as a respected panelist among regulatory agencies worldwide. She holds multiple clinical advisories, chair positions, and patents, exemplifying her commitment to advancing medical science and patient well-being. In addition to her exceptional career, Dr. Manax is a proud Belfast Ambassador recipient and was recently named as a government advisor to Northern Ireland for Health and Life Sciences, embodying her dedication to advancing healthcare on a global scale.